Cilcare’s Post

🚀 Cilcare Completes €40 Million Series A to Accelerate Development of Innovative Treatments for Early Hearing Loss 🎧 We are excited to announce the successful completion of our €40 million Series A funding round! This significant milestone will enable Cilcare to advance its mission to revolutionize treatments for hearing loss, with a focus on early-stage intervention. The funds will drive key initiatives, including: 🔹 Two Phase 2a clinical trials for our lead drug candidate, CIL001, targeting cochlear synaptopathy, a primary cause of speech comprehension difficulties, tinnitus, and hyperacusis. 🔹 Advancing the preclinical development of our second drug candidate, CIL003. 🔹 Strengthening our R&D platform capabilities and forming new strategic partnerships to expand our portfolio of treatments for hearing disorders. 🔹 Leveraging advanced AI technologies to identify auditory biomarkers, enabling better patient selection for clinical trials and more precise evaluation of treatment efficacy. A special thank you to our new investors, Shionogi & Co., Ltd, SPRIM Global Investments, for believing in our vision, and to our historic investors – SOFILARO, ARIS, SUD PME CROISSANCE, UVM Health Capital for their continued commitment. With your support, we are one step closer to realizing our ambition: delivering transformative treatments to millions of people affected by hearing disorders worldwide. Let’s make better hearing a reality. Access the full press release here: https://lnkd.in/djE5aUi9 #HearingLoss #Innovation #ClinicalTrials #ArtificialIntelligence #SeriesA #Healthcare #tinnitus #hyperacusis

  • graphical user interface, text, application, chat or text message
Stéphane Cruveiller

Driving Innovation in Biotech & Diagnostics | Transforming Data into Actionable Health Solutions | Expert in Bioinformatics & Genomics

1w

Félicitations pour cette levée majeure qui permet d'accélérer le développement de solutions innovantes contre la perte auditive !

Like
Reply
Frederic PLANCHE

De l’amorçage à la croissance de votre entreprise, notre challenge . Dir NEXTINNOV ,Banque Populaire du Sud. Région Occitanie.

1w

Quel Chemin 💪💪, depuis notre 1er échange fin. 2014. Quelle fierté pour vous , vos équipes , Montpellier et Banque Populaire du Sud qui vous accompagne depuis votre création. 💪🥂

Thomas Meyer

Chairman & CEO Altamira Therapeutics Ltd.

1w

Très bonne nouvelle, félicitations! 🚀

Franck Molina

Director of public-private research center chez Sys2Diag (CNRS - ALCEDIAG)

18h

Bravo #CeliaBeline c'est mérité !!!

Like
Reply
Yannis Boukari

On apaise durablement les acouphènes chroniques, sans médication, grâce à une approche unique, validée et fondée sur la science. Le point de départ, c'est vous — déjà une vie sauvée.

1w

Congratulations, this is impressive! The prospects Cilcare is aiming for are particularly promising ; great news for the entire ecosystem, and especially for future patients.

Félicitations à toute l’équipe !!! Congrats to the whole team !!! Well deserved !

Félicitations Celia Belline ! Vous donnez de l’espoir à des gens qui en ont tellement besoin !

Like
Reply
Christelle MATHIEU

Directrice Opérationnelle RESEAUX ET INGENIERIE DE HAUT DE BILAN

1w

trés fière de vous !!! Encore bravo

Like
Reply
Graham Dixon

Chief Executive Officer, Estetra SRL

1w

Congratulations Celia and team

Yanis Merabet

💊 I support Biotech Companies with their Clinical Trials

1w

Congratulations to the whole Cilcare team for this important milestones ! 👏🏻

See more comments

To view or add a comment, sign in

Explore topics